Literature DB >> 28603651

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing.

Luisella Righi1, Francesca Franzi2, Francesca Montarolo1, Gaia Gatti1, Massimo Bongiovanni3, Fausto Sessa4, Stefano La Rosa3.   

Abstract

In recent years, endobronchial ultrasound-guided TBNA (EBUS-TBNA) has emerged as an innovative technique for diagnosis and staging of lung cancer and has been successfully introduced into daily clinical practice with several advantages including minimally invasive approach, safe, cost-effective, real time image guidance, broad sampling capability, and rapid on-site evaluation (ROSE). Both cytological and histological approach could be useful to have material for diagnosis, immunohistochemical and molecular analyses which may be very important for targeted therapy with successful rate ranging from 89% to 98%. The utility of ROSE during EBUS-TBNA has been matter of debate. Indeed, although some evidence concluded that ROSE does not increase the diagnostic efficacy of EBUS-TBNA, other demonstrated that it improves the diagnostic yield of the procedure up to 30%, allows to avoid repetition of additional diagnostic procedures and reduces risk of complications. Furthermore the sample preparation by cytopathologist is optimized with the aid of direct macroscopic inspection, optimal smearing techniques, and triage of the sample permitting to obtain adequate tissue for diagnosis, ancillary techniques and molecular testing, when needed. Some pathological issues on EBUS-TBNA are reviewed and discussed with particular focus on ROSE and molecular testing.

Entities:  

Keywords:  ALK; EGFR; Endobronchial ultrasound-guided (EBUS); immunohistochemistry (IHC); lung cancer; transbronchial needle aspiration (TBNA)

Year:  2017        PMID: 28603651      PMCID: PMC5459867          DOI: 10.21037/jtd.2017.03.158

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  38 in total

1.  "The petals and thorns" of ROSE (rapid on-site evaluation).

Authors:  Gilda da Cunha Santos; Hyang-Mi Ko; Mauro Ajaj Saieg; William R Geddie
Journal:  Cancer Cytopathol       Date:  2012-07-03       Impact factor: 5.284

2.  Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.

Authors:  Agita Jukna; Gloria Montanari; Maria Cecilia Mengoli; Alberto Cavazza; Marisa Covi; Fausto Barbieri; Federica Bertolini; Giulio Rossi
Journal:  J Thorac Oncol       Date:  2015-12-30       Impact factor: 15.609

Review 3.  Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.

Authors:  Jordi Remon; Nathalie Chaput; David Planchard
Journal:  Curr Opin Oncol       Date:  2016-03       Impact factor: 3.645

4.  Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome.

Authors:  Luisella Righi; Tiziana Vavalà; Ida Rapa; Simona Vatrano; Jessica Giorcelli; Giulio Rossi; Enrica Capelletto; Silvia Novello; Giorgio V Scagliotti; Mauro Papotti
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

Review 5.  Guideline for the acquisition and preparation of conventional and endobronchial ultrasound-guided transbronchial needle aspiration specimens for the diagnosis and molecular testing of patients with known or suspected lung cancer.

Authors:  Erik H F M van der Heijden; Roberto F Casal; Rocco Trisolini; Daniel P Steinfort; Bin Hwangbo; Takahiro Nakajima; Birgit Guldhammer-Skov; Giulio Rossi; Maurizio Ferretti; Felix F J Herth; Rex Yung; Mark Krasnik
Journal:  Respiration       Date:  2014-11-05       Impact factor: 3.580

6.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Conventional vs endobronchial ultrasound-guided transbronchial needle aspiration: a randomized trial.

Authors:  Felix Herth; Heinrich D Becker; Armin Ernst
Journal:  Chest       Date:  2004-01       Impact factor: 9.410

8.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

9.  Impact of EBUS-TBNA on modalities for tissue acquisition in patients with lung cancer.

Authors:  R J José; P Shaw; M Taylor; D R Lawrence; P J George; S M Janes; N Navani
Journal:  QJM       Date:  2013-11-19

10.  EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods.

Authors:  Gerald Schmid-Bindert; Yongsheng Wang; Hongbin Jiang; Hui Sun; Thomas Henzler; Hao Wang; Lothar R Pilz; Shengxiang Ren; Caicun Zhou
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

View more
  7 in total

Review 1.  Endobronchial ultrasound-guided intranodal forceps biopsy (EBUS-IFB)-technical review.

Authors:  George Cheng; Amit Mahajan; Scott Oh; Sadia Benzaquen; Alexander Chen
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid EGFR/KRAS analysis in 43 cases.

Authors:  Maria-Rosa Ghigna; Adrian Crutu; Valentina Florea; Séverine Feuillet-Soummer; Pierre Baldeyrou; Julien Adam; Ludovic Lacroix; Benjamin Besse; Olaf Mercier; Elie Fadel; Peter Dorfmuller; Rida El Ayoubi; Vincent Thomas de Montpréville
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung Cancer.

Authors:  Roberto Martin-Deleon; Cristina Teixido; Carmen Mª Lucena; Daniel Martinez; Ainhoa Fontana; Roxana Reyes; Mireia García; Nuria Viñolas; Ivan Vollmer; Marcelo Sanchez; Pedro Jares; Francisco Manuel Pérez; Naiara Vega; Elba Marin; Ramón Mª Marrades; Carlos Agustí; Noemi Reguart
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 4.  Processing and Reporting of Cytology Specimens from Mediastinal Lymph Nodes Collected using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A State-of-the-Art Review.

Authors:  Inderpaul Singh Sehgal; Nalini Gupta; Sahajal Dhooria; Ashutosh Nath Aggarwal; Karan Madan; Deepali Jain; Parikshaa Gupta; Neha Kawatra Madan; Arvind Rajwanshi; Ritesh Agarwal
Journal:  J Cytol       Date:  2020-04-02       Impact factor: 1.000

5.  Neuroendocrine Tumor Diagnosed Through Endoscopic Ultrasound-Guided Fine-Needle Biopsy of a Lung Mass.

Authors:  Mohamed Abdallah; Nicholas McDonald; Brian Hanson; Gaurav Suryawanshi; Mohammad Bilal
Journal:  ACG Case Rep J       Date:  2022-09-01

Review 6.  Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA): Technical Updates and Pathological Yield.

Authors:  Huzaifa A Jaliawala; Samid M Farooqui; Kassem Harris; Tony Abdo; Jean I Keddissi; Houssein A Youness
Journal:  Diagnostics (Basel)       Date:  2021-12-10

7.  The changes on anesthetic practice for non-intubated bronchoscopic interventions during Covid-19 pandemic.

Authors:  Yi-Chun Lo; Su-Chuan Han; Ching-Kai Lin; Chung-Chih Shih; Ya-Jung Cheng
Journal:  J Formos Med Assoc       Date:  2021-07-12       Impact factor: 3.282

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.